EVR Research LP Purchases Shares of 400,000 Enfusion, Inc. (NYSE:ENFN)

EVR Research LP purchased a new stake in Enfusion, Inc. (NYSE:ENFN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 400,000 shares of the company's stock, valued at approximately $4,120,000. Enfusion comprises approximately 1.4% of EVR Research LP's investment portfolio, making the stock its 23rd largest holding. EVR Research LP owned approximately 0.31% of Enfusion as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Enfusion during the fourth quarter valued at about $75,000. Quantbot Technologies LP bought a new stake in Enfusion during the 4th quarter worth approximately $144,000. Intech Investment Management LLC bought a new position in shares of Enfusion during the fourth quarter valued at $191,000. Wells Fargo & Company MN lifted its holdings in shares of Enfusion by 46.8% during the fourth quarter. Wells Fargo & Company MN now owns 25,499 shares of the company's stock worth $263,000 after purchasing an additional 8,126 shares during the period. Finally, Fox Run Management L.L.C. bought a new stake in shares of Enfusion in the fourth quarter worth $265,000. Institutional investors and hedge funds own 81.05% of the company's stock.

Enfusion Trading Up 0.3 %

Shares of ENFN traded up $0.04 during trading hours on Thursday, reaching $10.84. The stock had a trading volume of 599,236 shares, compared to its average volume of 621,810. The firm has a 50-day simple moving average of $11.09 and a 200 day simple moving average of $10.39. Enfusion, Inc. has a 12 month low of $7.83 and a 12 month high of $11.80. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of 270.94, a P/E/G ratio of 1.85 and a beta of 0.92.

Enfusion (NYSE:ENFN - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). The business had revenue of $52.94 million during the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. On average, equities analysts forecast that Enfusion, Inc. will post 0.06 EPS for the current year.

Insider Activity at Enfusion

In related news, CFO Bradley Herring sold 4,645 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total value of $52,860.10. Following the sale, the chief financial officer now directly owns 324,689 shares in the company, valued at approximately $3,694,960.82. The trade was a 1.41 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Oleg Movchan sold 11,452 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $11.39, for a total transaction of $130,438.28. Following the sale, the chief executive officer now owns 631,847 shares in the company, valued at $7,196,737.33. The trade was a 1.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 66,223 shares of company stock worth $754,778. 36.44% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts recently commented on the company. Piper Sandler upped their target price on Enfusion from $10.00 to $11.50 and gave the company a "neutral" rating in a report on Monday, December 23rd. William Blair reissued a "market perform" rating on shares of Enfusion in a research note on Monday, January 13th. Finally, Stifel Nicolaus boosted their target price on shares of Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.